KBI Biopharma Recognized as a Leader in All Six Categories of the 2024 CDMO Leadership Awards

KBI Biopharma, a JSR Life Sciences Company and leading global Contract Development and Manufacturing Organization (CDMO) has received six awards in the 2024 CDMO Leadership Awards across all categories, including Capabilities, Compatibility, Expertise, Quality, and Reliability across the Small Pharma respondent type, Service Overall (which combines Big and Small Pharma), and the special Champion designation for Service among the Small Pharma respondents. The CDMO Leadership Awards are presented by Outsourced Pharma and Life Science Connect.

The awards recognize the CDMOs that meet or exceed their customers' expectations. 98 contract manufacturers were evaluated on 23 performance metrics based on research from Industry Standard Research (ISR) Reports’ Contract Manufacturing Quality Benchmarking annual online surveys. Following the surveys, KBI also received the following Individual Attribute Awards: Innovation, On-Time Delivery, Right First Time, State-of-the-Art, and Strength of Science.

“KBI Biopharma’s recognition as a leader in all categories of the 2024 CDMO Leadership Awards is absolutely thrilling. Our foundation is rooted in robust technical expertise, an entrepreneurial mindset, and an unyielding dedication to our partners, all of which have unequivocally contributed to this prestigious acknowledgment,” says J.D. Mowery, President and CEO of KBI Biopharma. “As a next-generation CDMO partner, we proactively steer our clients through the complexities of drug development, regulatory pathways, and commercialization, ensuring that groundbreaking treatments reach those who truly need them. It's a moment of immense pride for me to accept these six awards, representing our entire global network.”

“Congratulations to our 2024 CDMO Leadership Award winners. By vote of your customers, you are recognized as the best in the global outsourcing development and manufacturing sector of the biopharma industry,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. “Award winners maintained and expanded capabilities and expertise to meet the needs of a diverse customer base; provided the additional quality and reliability so crucial to novel processes and products; and forged the closest relationships with customers. 2023 rang in with many unsettled questions. The 2024 CDMO Leadership Award winners are the support companies that best answered the bell over the past year.”

“Industry Standard Research is proud to be a part of the CDMO Leadership Awards. ISR’s research methodology ensures that the people who participate in the contract manufacturing benchmarking market research are highly qualified decision-makers with first-hand experience working with the suppliers they evaluate. These awards are based on experiential feedback and enable users of ISR’s market research to make data-driven decisions with respect to choosing an outsourcing partner. It also means the winners of these awards have been delivering the highest quality of service according to their current and recent customers and are deserving of these accolades for their distinction.” Kate Hammeke, Vice President, Industry Standard Research.

Below are a few photos of some of our team members captured at the 2024 CDMO Leadership Awards Ceremony, held in New York City on March 20, 2024. Interested in learning more about the CDMO Leadership Awards? Visit the Awards website.

              

About KBI Biopharma, Inc.

KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.

Global partners are utilizing KBI’s technologies to advance more than 170 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.

KBI Biopharma, Inc. Company Inquiries
Sarah Wakefield
KBI Biopharma, Inc.
swakefield@kbibiopharma.com

KBI Biopharma, Inc. Media Inquiries
Blair Ciecko
CG Life
bciecko@cglife.com